Related Experiment Video
Updated: Jun 5, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in
Sonia Néron1, Philippe J Nadeau, André Darveau
1Ingénierie cellulaire, Recherche et développement, Héma-Québec, 1070 avenue des Sciences-de-la-Vie, Québec, QC, G1V 5C3, Canada. sonia.neron@hema-quebec.qc.ca
Insights
CD40 agonists like CD154 activate B lymphocytes, crucial for understanding immune responses. Diverse in vitro models reveal how CD40 signaling strength impacts B-cell function, aiding cellular therapy development.
Area of Science:
- Immunology
- Cell Biology
Background:
- B-lymphocyte activation is mediated by CD154 binding to CD40, a key receptor on B cells.
- In vitro models of CD40-stimulated B lymphocytes are vital for studying immune responses in health and disease.
Purpose of the Study:
- To review diverse CD40 agonists used in in vitro B-lymphocyte activation models.
- To emphasize variations in CD40 signaling strength generated by these models.
Main Methods:
- Review of various engineered CD40 ligands: monoclonal anti-CD40 antibodies, recombinant CD154 proteins, soluble CD154(+) membranes, and CD154(+) cell lines.
- Analysis of how parameters like contact duration, strength, timing, affinity, and receptor density affect CD40 binding.
- Examination of how varying CD40 stimulation intensity influences B-cell proliferation, differentiation, and immunoglobulin secretion.
Main Results:
- The diversity of CD40 agonists leads to variations in CD40 signaling strength.
- Different stimulation intensities differentially affect human hybridomas, B-cell lines, and primary B lymphocytes.
- Understanding these model variations is critical for interpreting experimental outcomes.
Conclusions:
- A comprehensive understanding of CD40 agonist diversity and their signaling outputs is essential.
- Optimizing in vitro models can enhance the use of human B lymphocytes in cellular therapies.
- Further research into CD40-CD154 interactions can unlock new therapeutic strategies.
Abstract:
Naive and memory B-lymphocyte populations can be activated through the binding of CD154 to CD40, a receptor that is constitutively expressed on the surface of these cells. Models based on the in vitro stimulation of human B lymphocytes through CD40 have greatly contributed to our understanding of the human immune response in healthy individuals and patients suffering from immune disorders. The nature of the engineered CD40 ligands is as diverse as the in vitro models used in studies of CD40-activated B lymphocytes. Monoclonal anti-CD40 antibodies, recombinant CD154 proteins, soluble CD154(+) membranes as well as CD154(+) cell lines have turned out to be very useful tools, and are still in use today. As for any receptor-ligand interaction, parameters such as duration and strength of contact, timing, affinity, and receptor density are major determinants of CD40 binding by CD154 or anti-CD40. Furthermore, variation in the intensity of CD40 stimulation has been shown to influence proliferation, differentiation and immunoglobulin secretion of human hybridomas, B-cell lines, tonsil and blood B lymphocytes. The objective of this review is to present an overview of the great diversity of CD40 agonists used in in vitro models of B-lymphocyte activation, with a particular emphasis on variations in the resulting strength of CD40 signaling generated by these models. A better understanding of these models could open up new avenues for the rational use of human B lymphocytes as antigen-presenting cells in cellular therapies.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...